

SHARPS COMPLIANCE CORP  
Form 10-Q  
February 13, 2009  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended December 31, 2008

☐ TRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number: 0-22390

---

SHARPS COMPLIANCE CORP.  
(Exact name of small business issuer as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

74-2657168  
(I.R.S. Employer Identification No.)

9220 Kirby Drive, Suite 500, Houston,  
Texas  
(Address of principal executive  
offices)

77054  
(Zip Code)

(713) 432-0300  
(Issuer's telephone number)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.

Large Accelerated  
Filer ☐

Accelerated  
Filer ☐

Non-accelerated  
Filer ☐  
(Do not check if a  
smaller reporting  
company)

Smaller reporting  
company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes ☐ No ☒

As of February 9, 2009, there were 12,921,280 outstanding shares of the Registrant's common stock, par value \$0.01 per share.

---

## SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

## INDEX

	PAGE
<b>PART I</b>	<b>FINANCIAL INFORMATION</b>
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets 3
	Condensed Consolidated Statements of Income for the three months ended December 31, 2008 and 2007 4
	Condensed Consolidated Statements of Income for the six months ended December 31, 2008 and 2007 5
	Condensed Consolidated Statements of Cash Flows 6
	Notes to Condensed Consolidated Financial Statements 7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations 9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk 17
Item 4.	Controls and Procedures 17
<b>PART II</b>	<b>OTHER INFORMATION</b>
Item 1.	Legal Proceedings 19
Item 4.	Submission of Matters to a Vote of Security Holders 19
Item 6.	Exhibits 19
<b>SIGNATURES</b>	<b>21</b>

PART I  
ITEM 1.FINANCIAL INFORMATION  
FINANCIAL STATEMENTSSHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2008 (Unaudited)	June 30, 2008
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 2,064,290	\$ 2,035,219
Restricted cash	-	10,010
Accounts receivable, net of allowance for doubtful accounts of \$14,985 and \$15,301, respectively	1,133,015	1,183,975
Inventory	830,640	580,861
Prepaid and other assets	343,638	359,894
Deferred income taxes	17,352	-
<b>TOTAL CURRENT ASSETS</b>	<b>4,388,935</b>	<b>4,169,959</b>
<b>PROPERTY AND EQUIPMENT</b> , net of accumulated depreciation of \$1,079,416 and \$933,129, respectively	<b>1,809,641</b>	<b>1,375,657</b>
<b>DEFERRED INCOME TAXES</b> , non current	<b>3,106,390</b>	<b>-</b>
<b>INTANGIBLE ASSETS</b> , net of accumulated amortization of \$153,748 and \$140,801, respectively	<b>152,932</b>	<b>130,702</b>
<b>TOTAL ASSETS</b>	<b>\$ 9,457,898</b>	<b>\$ 5,676,318</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 696,002	\$ 778,423
Accrued liabilities	245,470	432,971
Deferred revenue	1,134,994	1,063,016
<b>TOTAL CURRENT LIABILITIES</b>	<b>2,076,466</b>	<b>2,274,410</b>
<b>LONG-TERM DEFERRED REVENUE</b>	<b>633,178</b>	<b>516,372</b>
<b>TOTAL LIABILITIES</b>	<b>2,709,644</b>	<b>2,790,782</b>
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>STOCKHOLDERS' EQUITY</b>		
Common stock, \$0.01 par value per share; 20,000,000 shares authorized; 12,841,280 and 12,580,183 shares issued and outstanding, respectively	128,413	125,802

Edgar Filing: SHARPS COMPLIANCE CORP - Form 10-Q

Additional paid-in capital	10,895,236	9,225,342
Accumulated deficit	(4,275,395)	(6,465,608)
TOTAL STOCKHOLDERS' EQUITY	6,748,254	2,885,536
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 9,457,898	\$ 5,676,318

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	Three Months Ended December 31, 20082007 (Unaudited)	
REVENUES		
Product	\$ 3,247,581	\$ 3,642,065
Environmental and other services	122,065	108,737
TOTAL REVENUES	3,369,646	3,750,802
COSTS AND EXPENSES		
Cost of revenues	2,081,422	2,145,468
Selling, general and administrative	1,438,016	1,185,046
Depreciation and amoritization	82,854	65,920
TOTAL COSTS AND EXPENSES	3,602,292	3,396,434
OPERATING INCOME (LOSS)	(232,646)	354,368
OTHER INCOME (EXPENSE)		
Interest income	11,904	26,100
Other income (expense)	5,588	(6)
TOTAL OTHER INCOME	17,492	26,094
INCOME (LOSS) BEFORE INCOME TAXES	(215,154)	380,462
INCOME TAX EXPENSE (BENEFIT)		
Current	6,266	558
Deferred	(1,806,292)	-
TOTAL INCOME TAX EXPENSE (BENEFIT)	(1,800,026)	558
NET INCOME	\$ 1,584,872	\$ 379,904
NET INCOME PER COMMON SHARE		
Basic	\$ 0.12	\$ 0.03
Diluted	\$ 0.11	\$ 0.03
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOMER PER COMMON SHARE:		
Basic	12,841,280	12,157,441
Diluted	13,839,779	13,494,251

The accompanying notes are an integral part of these condensed consolidated financial statements.



SHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	Six Months Ended December 31, 20082007 (Unaudited)	
REVENUES		
Product	\$ 7,427,033	\$ 6,931,568
Environmental and other services	212,149	210,346
TOTAL REVENUES	7,639,182	7,141,914
COSTS AND EXPENSES		
Cost of revenues	4,501,783	4,103,203
Selling, general and administrative	2,600,971	2,340,427
Depreciation and amortization	159,234	123,617
TOTAL COSTS AND EXPENSES	7,261,988	6,567,247
OPERATING INCOME	377,194	574,667
OTHER INCOME (EXPENSE)		
Interest income	23,977	52,440
Other income (expense)	8,388	(44)
TOTAL OTHER INCOME	32,365	52,396
INCOME BEFORE INCOME TAXES	409,559	627,063
INCOME TAX EXPENSE (BENEFIT)		
Current	25,638	5,555
Deferred	(1,806,292)	-
TOTAL INCOME TAX EXPENSE (BENEFIT)	(1,780,654)	5,555
NET INCOME	\$ 2,190,213	\$ 621,508
NET INCOME PER COMMON SHARE		
Basic	\$ 0.17	\$ 0.05
Diluted	\$ 0.16	\$ 0.05
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOMER PER COMMON SHARE:		
Basic	12,751,844	12,109,845
Diluted	13,771,731	13,514,774

The accompanying notes are an integral part of these condensed consolidated financial statements.





SHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended December 31, 20082007 (Unaudited)	
CASH FLOWS FROM OPERATING ACTIVITES		
Net income	\$ 2,190,213	\$ 621,508
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	159,234	123,617
Stock based compensation expense	125,908	20,438
Excess tax benefits from stock-based award activity	(12,926)	(7,986)
Deferred tax benefit	(1,806,292)	-
Changes in operating assets and liabilities:		
Decrease in restricted cash	10,010	-
Decrease (increase) in accounts receivable	50,960	(65,212)
Increase in inventory	(249,779)	(174,278)
Decrease (increase) in prepaid and other assets	16,256	(15,304)
(Decrease) increase in accounts payable and accrued liabilities	(256,996)	12,820
Increase in deferred revenue	188,784	182,858
NET CASH PROVIDED BY OPERATING ACTIVITIES	415,372	698,461
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(580,271)	(268,395)
Additions to intangible assets	(35,177)	(49,465)
NET CASH USED IN INVESTING ACTIVITIES	(615,448)	(317,860)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on capital lease obligations	-	(1,809)
Excess tax benefits from stock-based award activity	12,926	7,986
Proceeds from exercise of stock options	216,221	153,040
NET CASH PROVIDED BY FINANCING ACTIVITIES	229,147	159,217
NET INCREASE IN CASH AND CASH EQUIVALENTS	29,071	539,818
CASH AND CASH EQUIVALENTS, beginning of period	2,035,219	2,134,152
CASH AND CASH EQUIVALENTS, end of period	\$ 2,064,290	\$ 2,673,970

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. ("Sharps e-Tools"), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, "Sharps" or the "Company"). All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2008 and the results of its operations for the three and six months ended December 31, 2008 and 2007 and the cash flows for the six months ended December 31, 2008. The results of operations for the three and six months ended December 31, 2008, are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2009. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended June 30, 2008.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

The Company complies with the Securities and Exchange Commission's ("SEC") Staff Accounting Bulletin ("SAB") No. 101, "Revenue Recognition", which provides guidance related to revenue recognition based on interpretations and practices followed by the SEC. Under SAB No. 101, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Disposal by Mail Systems, referred to as "Mailback" and Sharps Return Boxes, referred to as "Pump Returns") and can consist of up to three separate elements as follows: (1) the sale of the container system, (2) the transportation of the container system and (3) the treatment and disposal (incineration) of the container system. The individual fair value of the transportation and incineration services are determined by the sales price of the service offered by third parties, with the fair value of the container being the residual value. Revenue for the sale of the container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue on Mailbacks is recognized when the customer returns the mailback container system and the container has been received at the Company's treatment facility. The Mailback container system is mailed to the incineration facility using the United States Postal Service ("USPS") or United Parcel Service ("UPS"). Incineration revenue is recognized upon the destruction and certification of destruction having been prepared on the container. Since the transportation element and the incineration elements are undelivered services at the point of initial sale of the container, the Mailback revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a

portion of the transportation and incineration elements is recognized at the point of sale.

NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements; SFAS 157 is effective for fiscal years beginning after November 15, 2007 and for interim periods within those years. The FASB announced a one year deferral for the implementation of SFAS No. 157 for other non-financial assets and liabilities. In February, 2008, the FASB issued FASB Staff Position No. FAS 157-2. This FSP defers the effective date of Statement 157 for non-financial assets and liabilities on a recurring basis (at least annually) to fiscal years beginning after November 15, 2008, and interim periods within those fiscal years for items within the scope of this FSP. The Company adopted SFAS No. 157 effective July 1, 2008, except for non financial assets and liabilities as permitted by FSP SFAS 157-2, and the adoption of such statement did not have a significant impact on our consolidated results of operations or financial position.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of FASB Statement No. 115." This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value and establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provisions of SFAS No. 157. The Company adopted SFAS 159 effective July 1, 2008. The Company elected to not fair value any additional financial instruments and thus the adoption of the standard did not have a material impact on its financial position and results of operations.

#### NOTE 5 - INCOME TAXES

During the quarter ended December 31, 2008, the Company evaluated the valuation allowance on the deferred tax asset balances. As a result, the Company determined it was more likely than not that they would realize these deferred tax assets and as such the valuation allowance was reduced to zero. In addition to the above, the Company recorded a current income tax provision relating to AMT and state income taxes of \$6,266 and \$558 for the quarters ended December 31, 2008 and 2007, respectively. The current tax provision recorded for the six months ended December 31, 2008 and 2007 relating to AMT and state income taxes is \$25,638 and \$5,555, respectively. As of December 31, 2008 there were deferred tax assets of \$3,123,742, \$17,352 of which are current.

#### NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

The Company maintains a Credit Agreement with JPMorgan Chase Bank, N.A. ("Credit Agreement") which provides for a \$2.5 million Line of Credit Facility, the proceeds of which may be utilized for, (i) working capital, (ii) letters of credit (up to \$200,000), (iii) acquisitions (up to \$500,000) and (iv) general corporate purposes. Indebtedness under the Credit Agreement is secured by substantially all of the Company's assets. As of December 31, 2008 and June 30, 2008 respectively, no amounts related to the Credit Agreement were outstanding. Under the Credit Agreement and based upon the Company's December 31, 2008 level of accounts receivable and inventory, the amount available to borrow at quarter end was \$1.6 million. Interest expense under the line of credit is computed at prime (currently 3.25% per annum).

#### NOTE 7 – STOCK-BASED COMPENSATION

The Company accounts for share-based compensation under the provisions of Statement of Financial Accounting Standards No. 123R, ("SFAS 123R") Share-Based Payment, which establishes accounting for equity instruments exchanged for employee services. Under the provisions of SFAS No. 123R, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity grant). Share-based compensation expense, included in general and administrative expenses in the Company's consolidated statements of income for the three and six months ended December 31, 2008 was \$37,063 and \$125,908, respectively. The expense for the three and six months ended December 31, 2007 was (\$9,022) and \$20,438, respectively. SFAS No. 123R requires any reduction in taxes payable resulting from tax deductions that exceed the recognized tax benefit associated with compensation expense (excess tax benefits) to be classified as financing cash flows. The Company included \$8,276 and \$12,926 excess tax benefits in its cash flows from financing activities for the three and six months ended December 31, 2008, respectively. The Company included \$0 and \$7,986 excess tax benefits in its cash flows from financing activities for the three and six months ended December 31, 2007, respectively.

#### NOTE 8 - EARNINGS PER SHARE

Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. The following information is necessary to calculate earnings per share for the periods presented:

	Six Months Ended December 31,	
	2008	2007
	(Unaudited)	
Net income, as reported	\$ 2,190,213	\$ 621,508
Weighted average common shares outstanding	12,751,844	12,109,845
Effect of dilutive stock options	1,019,887	1,404,929
Weighted average diluted common shares outstanding	13,771,731	13,514,774
Net income per common share		
Basic	\$ 0.17	\$ 0.05
Diluted	\$ 0.16	\$ 0.05
Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive	335,000	75,000

## NOTE 9 - STOCK TRANSACTIONS

During the quarter ended December 31, 2008, stock options to purchase 50,000 of common shares were exercised. Total proceeds to the Company were \$55,000 (average price of \$1.10 per share). During the quarter ended December 31, 2007 stock options to purchase 30,000 of common shares were exercised. Total proceeds to the Company were \$30,800 (average price of \$1.03 per share).

During the six months ended December 31, 2008, stock options to purchase 244,600 shares of common shares were exercised. Total proceeds to the Company were \$216,221 (average price of \$.88 per share). During the six months ended December 31, 2007, stock options to purchase 186,730 of common shares were exercised. Total proceeds to the Company were \$153,040 (average price of \$0.82 per share).

## ITEM 2.

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

## INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to Sharps that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. When used in this report, the words "anticipate," "believe," "estimate" and "intend" and words or phrases of similar import, as they relate to Sharps or Company management, are intended to identify forward-looking statements. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. The Company does not intend to update these forward-looking statements.

## GENERAL

Sharps is a leading developer and manufacturer of cost effective solutions for improving safety, efficiency and costs related to the proper disposal of medical waste by industry and consumers. Sharps primary markets include healthcare, retail, agriculture, hospitality, professional, industrial, commercial, governmental and pharmaceutical. The Company's products and services represent solutions for industries and consumers dealing with the complexity of managing regulatory compliance, environmental sensitivity, employee and customer safety, corporate risk and operating costs related to medical waste disposal. Sharps is a leading proponent and participant in the development of public awareness and solutions for the safe disposal of needles, syringes and other sharps in the community setting.

The Company's products include Sharps Disposal by Mail System®, Pitch-It™ IV Poles, Trip LesSystem®, Sharps Pump Return Box, Sharps Enteral Pump Return Box, Sharps Secure®, Sharps SureTemp Tote®, IsoWash® Linen Recovery System, RxTakeAway™, 18 gallon Medical Professional Sharps Disposal by Mail System®, Biohazard Spill Clean-Up Kit and Disposal System, Sharps e-Tools, Sharps Environmental Services and Sharps Consulting.



The Sharps®MWMS™, a Medical Waste Management System service offering, is a comprehensive medical waste solution which includes an array of services and products necessary to effectively collect, store and dispose of medical waste in the alternate site market (i.e., outside of the hospital or large healthcare facility setting) . The System, which is designed for rapid deployment, features the Sharps Disposal By Mail System® products combined with warehousing, inventory management, training, data and other services necessary to provide a comprehensive solution. The Sharps®MWMS™ is designed to be an integral part of governmental and commercial emergency preparedness programs.

Some products and services facilitate compliance with state and federal regulations by tracking, incinerating and documenting the disposal of medical waste. Additionally, some products and services facilitate compliance with educational and training requirements required by federal, state, and local regulatory agencies.

## RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results of the Company during the three and six months ended December 31, 2008 and 2007.

The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Income, expressed as a percentage of revenue (unaudited):

	Three Months Ended December 31, 2008          2007 (Unaudited)		Six Months Ended December 31, 2008          2007 (Unaudited)	
Net revenues	100%	100%	100%	100%
Costs and expenses				
Cost of revenues	(62%)	(57%)	(59%)	(57%)
Selling, general and administrative	(43%)	(32%)	(34%)	(33%)
Depreciation and amortization	(2%)	(2%)	(2%)	(2%)
Total operating expenses	(107%)	(91%)	(95%)	(92%)
Income (loss) from operations	(7%)	9%	5%	8%
Total other income (expense)	1%	1%	0%	1%
Income tax expense (benefit)	53%	0%	23%	0%
Net income	47%	10%	29%	9%

## THREE MONTHS ENDED DECEMBER 31, 2008 AS COMPARED TO THREE MONTHS ENDED DECEMBER 31, 2007

Total revenues for the three months ended December 31, 2008 of \$3,369,646 decreased by \$381,156, or 10%, from the total revenues for the three months ended December 31, 2007 of \$3,750,802. Customer billings by market are as follows:

	Three-Months Ended December 31,		
	2008	2007	Variance
	(unaudited)	(unaudited)	(unaudited)
<b>BILLINGS BY MARKET:</b>			
Health Care	\$ 1,709,000	\$ 1,933,695	\$ (224,695)
Retail	455,077	315,115	139,962
Professional	313,157	168,317	144,840
Hospitality	221,791	306,779	(84,988)
Pharmaceutical	144,512	491,157	(346,645)
Commercial	110,212	160,137	(49,925)
Non-Mailable	92,972	116,253	(23,281)
Agriculture	92,617	173,694	(81,077)
Other	36,634	35,072	1,562
Government	65,647	85,090	(19,443)
Subtotal	3,241,619	3,785,309	(543,690)
GAAP Adjustment *	128,027	(34,507)	162,534
Revenue Reported	\$ 3,369,646	\$ 3,750,802	\$ (381,156)

\*Represents the net impact of the revenue recognition adjustment required to arrive at reported GAAP revenue. Customer billings includes all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with product returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company's balance sheet as deferred revenue. See Note 3 "Revenue Recognition" in Part I, "Notes to Consolidated Financial Statements".

The decrease in revenues is primarily attributable to decreased billings in the Pharmaceutical (\$346,645), Health Care (\$224,695), Hospitality (\$84,988), Agriculture (\$81,077), Commercial (\$49,925), Non-mailable (\$23,281) and Government (\$19,443) markets. These decreases were partially offset by increased billings in the Retail (\$139,962), Professional (\$144,840) and Other (\$1,562) markets. The decrease in the Pharmaceutical market is related to the timing of billings to a top ten pharmaceutical manufacturer which billed in the December 31, 2007 quarter prior year (\$429K) with no corresponding billing in the quarter ended December 31, 2008. This decrease was partially offset by billings to two major pharmaceutical manufacturers and billings to a major mail order pharmacy, all of which total \$119,615 for the quarter ended December 31, 2008. The decrease in the Health Care market is related to the consolidation of two key home healthcare companies and resulting purchasing efficiencies. The decrease in the Hospitality market is primarily attributable to a large order of Biohazard Spill Clean-Up Kits in the quarter ended December 30, 2007 with no corresponding billing in the quarter ended December 31, 2008. The decrease in the Agriculture market is primarily attributable to timing of orders and billings of the Sharps Disposal by Mail System® to a customer serving the Agriculture market. The decrease in Commercial market is related to a large initial order placed in the prior fiscal year quarter for a large corporation with locations across the country with no corresponding billing in the quarter ended December 31, 2008. The increase in the Retail market is a result of the strong flu shot business whereby the Company's flagship Sharps Disposal By Mail System® products are used in the retail setting to collect and properly dispose syringes used to administer flu shots. The increase in the Professional and Retail markets is being driven by higher demand for the Company's products as industry and consumers become more aware of the proper disposal of medical sharps (syringes, lancets, etc.).

Cost of revenues for the three months ended December 31, 2008 of \$2,081,422 was 62% of revenues. Cost of revenues for the three months ended December 31, 2007 of \$2,145,468 was 57% of revenue. Gross margin was negatively impacted by the lower revenue (i.e. lower coverage of fixed cost components in COGS) and mix of products sold (i.e. lower high margin Sharps Disposal By Mail Systems® sold as a percentage of total products). The current quarter gross margins were also adversely impacted by an increase in operations infrastructure costs as the Company prepares for higher sales volumes including those anticipated from the recent U.S. Government contract award.

Selling, general and administrative (“S, G & A”) expenses for the three months ended December 31, 2008 of \$1,438,016, increased by \$252,970, from S, G & A expenses for the three months ended December 31, 2007. The increase in S, G & A expense was primarily due to higher (i) non-cash 123(R) stock-based compensation expense of \$46,085, (ii) professional fees of \$43,860 (iii) compensation expense of \$39,765, (iv) payroll taxes of \$28,592, (v) recruiting fees of \$23,849 and (vi) housing-related costs for the Company’s new President and COO of \$17,986. The increase in non-cash 123(R) stock-based award expense was primarily due to the expense associated with the award of restricted stock in October 2008 to the Company’s recently appointed President and COO. The increase in professional fees was a result of expenses associated with, (i) various regulatory filings, (ii) outside consultation related to the recent U.S. Government contract award, (iii) S-8 (Sharps Compliance 1993 Stock Plan) preparation and related filing expenses, and (iv) legal fees associated with general corporate matters. The increase in compensation expense is due primarily to the hiring of a new President and COO in October 2008. Payroll taxes increased resulting from (i) increased compensation expense and corresponding Company paid portion of payroll tax, (ii) the Company portion of payroll taxes generated from the imputed income related to the October 2008 restricted stock award to the Company’s new President and COO and (iii) the Company portion of payroll taxes generated by the imputed income related to the exercise of employee stock options. The increased recruiting fees were associated to the hiring of two professions (sales and marketing).

## Edgar Filing: SHARPS COMPLIANCE CORP - Form 10-Q

The Company generated operating loss of \$232,646 for the three months ended December 31, 2008 compared to operating income of \$354,368 for the three months ended December 31, 2007. The operating loss is a result of the above mentioned decrease in revenue (and corresponding reduction in gross profit) and the increase in S, G & A expense (discussed above).

The Company generated a pre-tax loss of \$215,154 for the three months ended December 31, 2008 versus a pre-tax income of \$380,462 for the three months ended December 31, 2007. The decrease in pre-tax income is a result of lower operating income (discussed above). The Company generated net income of \$1,584,872 for the three months ended December 31, 2008 compared to net income of \$379,904 for the three months ended December 31, 2007. The increase in net income is a result of the reduction in the deferred tax valuation allowance of \$1,806,292 and corresponding credit to tax expense (see Note 5 of the Notes to the Condensed Consolidated Financial Statements).

The Company reported diluted earnings per share of \$0.11 for the three months ended December 31, 2008 versus diluted earnings per share of \$0.03 for the three months ended December 31, 2007. The increase in diluted earnings per share is a result of higher net income (discussed above).

### SIX MONTHS ENDED DECEMBER 31, 2008 AS COMPARED TO SIX MONTHS ENDED DECEMBER 31, 2007

Total revenues for the six months ended December 31, 2008 of \$7,639,182 increased by \$497,268, or 7%, over the total revenues for the six months ended December 31, 2007 of \$7,141,914. Customer billings by market are as follows:

	Six-Months Ended December 31,		
	2008	2007	Variance
	(unaudited)	(unaudited)	(unaudited)
<b>BILLINGS BY MARKET:</b>			
Health Care	\$ 3,615,697	\$ 3,852,959	\$ (237,262)
Retail	1,295,839	1,000,551	295,288
Professional	561,598	339,501	222,097
Hospitality	431,244	670,014	(238,770)
Pharmaceutical	1,019,125	498,342	520,783
Commercial	294,711	276,246	18,465
Non-Mailable	223,325	241,523	(18,198)
Agriculture	266,628	266,998	(370)
Other	74,789	84,276	(9,487)
Government	120,797	141,151	(20,354)
Subtotal	7,903,753	7,371,561	532,192
GAAP Adjustment *	(264,571)	(229,647)	(34,924)
Revenue Reported	\$ 7,639,182	\$ 7,141,914	\$ 497,268

\*Represents the net impact of the revenue recognition adjustment required to arrive at reported GAAP revenue. Customer billings includes all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with product returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company's balance sheet as deferred revenue. See Note 3 "Revenue Recognition" in Part I, "Notes to Consolidated Financial Statements".

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical (\$520,783), Retail (\$295,288), Professional (\$222,097), and Commercial (\$18,465) markets. These increases were partially offset by

decreased billings in the Hospitality (\$238,770), Health Care (\$237,262), Government (\$20,354), Non-mailback (\$18,198) and Other (\$9,487) markets. The increase in the Pharmaceutical market is led by increased billings to the Company's first contract with a top ten pharmaceutical manufacturer for the six months ended December 31, 2008 of \$683 thousand compared to \$429 thousand in billings for the six months ended December 31, 2007. Additionally, billings in the Pharmaceutical market increased as a result of billings to two major pharmaceutical manufacturers and billings to a major mail order pharmacy, all of which total \$294,355 for the six-months ended December 31, 2008. The increase in the Retail market is a result of the strong flu shot business whereby the Company's flagship Sharps Disposal By Mail System® products are used in the retail setting to collect and properly dispose of syringes used to administer flu shots. The increase in the Professional and Commercial markets is being driven by higher demand for the Company's products as industry and consumers become more aware of the proper disposal of medical sharps (syringes, lancets, etc.). The decrease in the Hospitality market is primarily attributable to a large order of Biohazard Spill Clean-Up Kits in the six months ended December 30, 2007 with no corresponding billing in the corresponding period ended December 31, 2008. The decrease in the Health Care market billings is related to the consolidation of two key home healthcare companies and resulting purchasing efficiencies.

## Edgar Filing: SHARPS COMPLIANCE CORP - Form 10-Q

Cost of revenues for the six months ended December 31, 2008 of \$4,501,783 was 59% of revenues. Cost of revenues for the six months ended December 31, 2007 of \$4,103,203 was 57% of revenue. Gross margin was negatively impacted during the six months ended December 31, 2008 by approximately \$200 thousand due to excess air freight shipping costs that were incurred to address supply and manufacturing issues associated with the Company's Pitch-It IV Poles. These issues were consequently resolved in the quarter ended September 30, 2008. Excluding the \$200 thousand in excess air freight shipping costs, the gross margin for the six months ended December 31, 2008 was 44%. The current quarter gross margins were also adversely impacted by an increase in operations infrastructure costs as the Company prepares for higher sales volumes including those anticipated from the recent U.S. Government contract award.

Selling, general and administrative ("S, G & A") expenses for the six months ended December 31, 2008 of \$2,600,971, increased by \$260,544, from S, G & A expenses for the six months ended December 31, 2007. The increase in S, G & A expense was primarily due to higher (i) non-cash 123(R) stock based compensation expense of \$105,470, (ii) professional fees of \$66,918 (iii) compensation expense of \$44,036, (iv) payroll taxes of \$27,546 and (v) housing-related costs for the Company's new President and COO of \$17,986. The increase in non-cash 123(R) stock-based award expense was primarily due to the expense associated with the award of restricted stock in October 2008 to the Company's recently appointed President and COO. The increase in professional fees was a result of expenses associated with, (i) various regulatory filings, (ii) outside consultation related to the recent U.S. Government contract award, (iii) S-8 (Sharps Compliance 1993 Stock Plan) preparation and related filing expenses, and (iv) legal fees associated with general corporate matters. The increase in compensation expense is due primarily to the hiring of a new President and COO in October 2008. Payroll taxes increased resulting from (i) increased compensation expense and corresponding Company paid portion of payroll tax, (ii) the Company portion of payroll taxes generated from the imputed income related to the October 2008 restricted stock award to the Company's new President and COO and (iii) the Company portion of payroll taxes generated by the imputed income related to the exercise of employee stock options.

The Company generated operating income of \$377,194 for the six months ended December 31, 2008 compared to \$574,667 for the six months ended December 31, 2007. The decrease in operating income is a result of the above mentioned increase in cost of revenues and S, G & A.

The Company generated income before tax of \$409,599 for the six months ended December 31, 2008 versus a pre-tax income of \$627,063 for the six months ended December 31, 2007. The decrease in income before tax is a result of lower operating income (discussed above).

The Company generated net income of \$2,190,213 for the six months ended December 31, 2008 compared to net income of \$621,508 for the six months ended December 31, 2007. The increase in net income is a result of the reduction in the deferred tax valuation allowance of \$1,806,292 and corresponding credit to tax expense (see Note 5 of the Notes to the Condensed Consolidated Financial Statements).

The Company reported diluted earnings per share of \$0.16 for the six months ended December 31, 2008 versus diluted earnings per share of \$0.05 for the six months ended December 31, 2007. The increase in diluted earnings per share is a result of higher net income (discussed above).

## PROSPECTS FOR THE FUTURE

The Company continues to take advantage of the many opportunities in the markets served as communities, consumers and industries become more aware of the proper disposal of medical sharps (syringes, lancets, etc.). This education process was enhanced in March 2004 when the U. S. Environmental Protection Agency ("EPA") issued its new guidelines for the proper disposal of medical sharps (see [www.epa.gov/epaoswer/other/medical/sharps.htm](http://www.epa.gov/epaoswer/other/medical/sharps.htm)). Additionally, in July 2006 both the states of California and Massachusetts passed legislation designed to mandate appropriate disposal of sharps waste necessary to protect the

general public and workers from potential exposure to contagious diseases and health and safety risks. In August 2008, the U.S. House of Representatives and U.S. Senate introduced bills 3251 and 1909, respectively, which would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes. Among the methods of disposal recommended as part of the above noted regulatory actions are mail-back programs such as those marketed by the Company. The Company estimates that there are an estimated 2 - 3 billion used syringes disposed of in the United States outside of the hospital setting. Additionally, the Company estimates that it would require 30 – 40 million Sharps Disposal by Mail System® products to properly dispose of all such syringes, which would equate to a \$1 billion small quantity generator market opportunity. Based upon the current level of sales, the Company estimates that this \$1 billion market has only been penetrated by approximately 1% or less.

The Company continues to develop new products for its Sharps Disposal by Mail System®, including the new RxTakeAway™ and 18 gallon Medical Professional Sharps Disposal by Mail System®, and Sharps SureTemp Tote® product lines. The Company is also developing products designed to facilitate the proper and cost effective disposal of unused medications. The Company believes its future growth will be driven by, among other items, (i) the positive impact and awareness created by the above noted regulatory actions as well as additional potential future legislation, (ii) the effects of the Company's extensive direct marketing efforts and (iii) the Company's leadership position in the development and sale of products designed to properly and cost effectively dispose of small quantities of medical waste.

Demand for the Company's primary product, the Sharps Disposal by Mail System®, which facilitates the proper and cost-effective disposal of medical waste including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin (referred to as "sharps"), has been growing rapidly in the small quantity generator sector because of its mail-back convenience and unique data tracking feature. In addition, targeted opportunities continue to expand as a result of, (i) legislation mandating the proper disposal of sharps, (ii) the growing awareness of the need to properly handle sharps medical waste for safety and environmental concerns, (iii) the significant increase in self-injectable medications and (iv) the changing paradigm in the healthcare industry.

On February 2, 2009, the Company announced a \$40 million contract award to provide its Sharps Medical Waste Management System ("Sharps®MWMS™") to an agency of the United States Government. The total contract is valued at approximately \$40 million and is expected to be executed over a five year period. The Company has received a purchase order for \$28.5 million which represents product and services to be provided during the first contract year. The following four option years represent payment for program maintenance.

The Company estimates that it will recognize revenue on the above noted Government contract as follows (i) \$6 million in FY 2009, (ii) \$23 million in FY 2010, (iii) \$3 million in FY 2011, (iv) \$3 million in FY 2012, (v) \$3 million in FY 2013 and (vi) \$2 million in FY 2014.

The above amounts are estimates only and are subject to change. Although the Company believes the amounts above to be reasonable based upon its current project plan, it makes no assurances regarding the actual recognition of revenue by fiscal year which could vary significantly from that noted above.

## LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents increased by \$29,071 to \$2,064,290 at December 31, 2008 from \$2,035,219 at June 30, 2008. The increase in cash and cash equivalents is primarily a result of cash generated from operations of \$415,371 plus proceeds from the exercise of stock options of \$216,221 partially offset by additions to property and equipment and intangible assets of \$615,447.

Accounts receivable decreased by \$50,960 to \$1,133,015 at December 31, 2008 from \$1,183,975 at June 30, 2008.

Inventory increased by \$249,779 to \$830,640 at December 31, 2008 from \$580,861 at June 30, 2008. The increase in inventory is attributable to recent bulk purchases of Sharps Secure® and poles manufactured overseas and additional stock needed for specialty orders.

Deferred income tax benefits of \$3,123,742 were booked in the quarter ended December 31, 2008 due to the Company's decision to reduce the deferred tax valuation allowance to zero. The decision was made after evaluation the following circumstances (i) recent \$40 million U.S. Government contract award to the Company and the corresponding anticipated taxable income, (ii) the anticipated taxable income for third and fourth quarters of fiscal 2009 and the full fiscal year 2010 and (iii) the expected utilization in fiscal 2009 and 2010 of the remaining net operating loss carry forward.



Property and equipment increased by \$433,984 to \$1,809,641 at December 31, 2008 from \$1,375,657 at June 30, 2008 due to capital expenditures of \$580,271 partially offset by depreciation expense of \$146,287. The capital expenditures are attributable primarily to, (i) treatment facility improvements of \$298,057 (ii) new system software and implementation of \$93,632, (iii) Autoclave permitting costs of \$76,350, (iv) molds, dies and printing plates for production of \$48,181, (v) warehouse/operations-related equipment of \$45,928, (vi) custom software programming of \$11,136 and (vii) office furniture of \$1,881. The treatment facility improvements represent (i) capital expenditures related to the estimated third quarter fiscal year 2009 autoclave technology installation and (ii) general facility improvements. The new system software and implementation costs were related to the implementation of a new integrated sales, operations and financial system in December 2008. The warehouse/operations-related equipment was related to equipment necessary to accommodate the automation of in-house assembly of the Company's products. The molds and printing plates were procured for development of new product and additional production capacity.

Accounts payable decreased by \$82,421 to \$696,002 at December 31, 2008 from \$778,423 at June 30, 2008. The decrease is a result in the timing of payments for product purchased and capital expenditures.

Accrued liabilities decreased by \$187,501 to \$245,470 at December 31, 2008 from \$432,971 at June 30, 2008. The decrease is a result of timing in the receipt of invoices for product received and payment of related amounts.

Stockholder's equity increased by \$3,862,718 from \$2,885,536 to \$6,748,254. This increase is attributable to, (i) net income for the six months ended December 31, 2008 of \$2,190,213, (ii) the increase in additional paid-in capital of \$1,317,450 resulting from the reduction of the deferred tax valuation allowance (See Note 5 of the Notes To Condensed Consolidated Financial Statements) (iii) the effect of the exercise of stock options to purchase 244,600 common stock with proceeds of \$216,221 (average exercise price of \$0.88) to the Company, (iv) the effect on equity (credit) of SFAS 123R non-cash stock-based compensation expense of \$125,908 and (v) the excess tax benefits from stock-based award activity of \$12,926.

On October 27, 2008, the Company appointed John R. Grow as its new President and Chief Operating Officer. In conjunction with this appointment, Mr. Grow received a grant of 300,000 restricted shares of unregistered Company common stock (i.e., issued outside of the Company's 1993 Stock Plan). The Company recorded non-cash stock-based compensation expense related to this grant of \$48,935 during the quarter ended December 31, 2008 and expects to record approximately \$65,000 during the quarter ended March 31, 2009, and approximately \$70,000 during each quarter, thereafter, until the quarter ended September 30, 2010. Non-cash stock based compensation expense is reflected in the Company's Statement of Income as a component of S, G & A expense. In conjunction with his employment agreement, the Company is providing Mr. Grow with housing and related arrangements. The annual cost of this arrangement is estimated to be \$96,000 and is reflected in the Company's Statement of Income as a component of S, G & A expense.

As noted above, The Company was recently awarded a \$40 million contract to provide its Sharps®MWMS™ to an agency of the U.S. Government. The Company believes it will need up to \$4 million in working capital over the first six months of the project. The Company currently has approximately \$2 million in cash on hand as well as a \$2.5 million line of credit with JPMorgan Chase (see note 6 of the Notes to Condensed Consolidated Financial Statements) with no amounts currently drawn. The Company has completed preliminary negotiations with the Bank to increase the line of credit to \$4.5 million. Although, no assurance can be made, the Company believes it will have its new line of credit facility in place by the quarter ended March 31, 2009.

Management believes that the Company's current cash resources (cash on hand and cash generated from operations) along with its line of credit facility will be sufficient to fund operations for the twelve months ending December 31, 2009.

#### Disposal Facility

In January 2008, Company purchased its previously leased disposal facility in Carthage, Texas. The purchase included an incinerator with a maximum capacity of thirty (30) tons per day, a 12,000 square foot building and 4.5 acres of land. The Company incinerator is currently permitted at a capacity of eleven (11) tons per day.

Additionally, the Company has executed a purchase order for a state-of-the-art autoclave system and technology capable of treating up to seven (7) tons per day of medical waste at the same facility. Autoclaving is a process that treats medical waste with steam at high temperature and pressure to kill pathogens. An autoclave is environmentally cleaner and is a less costly method of treating most medical waste versus traditional incineration. The autoclave is expected to be placed in service during the quarter ended March 31, 2009.

With the addition of the autoclave, the Company believes it will own one of only approximately ten (10) permitted commercial disposal facilities in the country capable of treating all types of medical waste.

The total cost of (i) the treatment facility purchase, (ii) addition of the autoclave technology and (iii) facility improvements is estimated to be approximately \$1.1 million with \$744,558 incurred to date. The remainder (which

consists primarily of the autoclave equipment and facility improvements) is expected to be incurred during the quarter ended March 31, 2009.

In November 2005, the EPA amended the Clean Air Act which will affect the operations of the incineration facility located in Carthage, Texas. The regulation modifies the emission limits and monitoring procedures required to operate an incineration facility. The new rules will necessitate changes to the Company's owned incinerator and pollution control equipment at the facility or require installation of an alternative treatment method to ensure compliance. Such change would require the Company to incur significant capital expenditures in order to meet the requirements of the regulations. The regulation allows a minimum period of three years and a maximum of five years to comply after the date the final rule was published. The Company has studied the amended EPA Clean Air Act and its options, and has decided in the interim to move forward with the process of adding alternative technology, autoclaving, for medical waste disposal with plans to be fully operational by March 31, 2009 at its current facility in Carthage, Texas. Autoclaving is a process that treats regulated waste with steam at high temperature and pressure to kill pathogens. Combining the autoclaving with a shredding or grinder process allows the waste to be disposed in a landfill operation. The Company believes autoclaving is environmentally cleaner and a less costly method of treating medical waste than incineration. The Company has not yet decided if and when it will incur the additional capital expenditures needed in order to meet the new regulations. The additional capital expenditures are estimated at approximately \$1.4 million and would increase its permitted incineration capacity from eleven (11) tons per day to thirty (30) tons per day. Should the Company incur such additional capital expenditures, it would do so subsequent to the development and launching of a business plan designed to generate significant incremental and new revenue stream from third party medical waste services.

## CRITICAL ACCOUNTING ESTIMATES

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points and can consist of up to three separate elements as follows: (1) the sale of the container system, (2) the transportation of the container system and (3) the treatment and disposal (incineration) of the container system. Since the transportation element and the incineration elements are undelivered services at the point of initial sale of the container, the revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a portion of the transportation and incineration elements is recognized at the point of sale.

### Governmental Regulation

#### Operations and Incinerator

Sharps is required to operate within guidelines established by federal, state, and/or local regulatory agencies. Such guidelines have been established to promote occupational safety and health standards and certain standards have been established in connection with the handling, transportation and disposal of certain types of medical and solid wastes, including mailed sharps. Sharps believes that it is currently in compliance in all material respects with all applicable laws and regulations governing its business. However, in the event additional guidelines are established to more specifically control the business of Sharps, including the environmental services subsidiary, additional expenditures may be required in order for Sharps to be in compliance with such changing regulations. Furthermore, any material relaxation of any existing regulatory requirements governing the transportation and disposal of medical sharps products could result in a reduced demand for Sharps' products and services and could have a material adverse effect on Sharps' revenues and financial condition. The scope and duration of existing and future regulations affecting the medical and solid waste disposal industry cannot be anticipated and are subject to change due to political and economic pressures.

In November 2005, the EPA amended the Clean Air Act which will affect the operations of the leased incineration facility located in Carthage, Texas. The regulation modifies the emission limits and monitoring procedures required to operate an incineration facility. The new rules will necessitate changes to the Company's owned incinerator and pollution control equipment at the facility or require installation of an alternative treatment method to ensure compliance. Such change would require the Company to incur significant capital expenditures in order to meet the requirements of the regulations. The regulation allows a minimum period of three years and a maximum of five years to comply after the date the final rule was published. The Company has studied the amended EPA Clean Air Act and its options, and has decided in the interim to move forward with the process of adding alternative technology, autoclaving, for medical waste disposal with plans to be fully operational by March 31, 2009 at its current facility in Carthage, Texas. Autoclaving is a process that treats regulated waste with steam at high temperature and pressure to kill pathogens. Combining the autoclaving with a shredding or grinder process allows the waste to be disposed in a landfill operation. The Company believes autoclaving is environmentally cleaner and a less costly method of treating medical waste than incineration. The Company has not yet decided if and when it will incur the additional capital expenditures needed in order to meet the new regulations. The additional capital expenditures are estimated at approximately \$1.4 million and would increase its permitted incineration capacity from eleven (11) tons per day to thirty (30) tons per day. Should the Company incur such additional capital expenditures, it would do so subsequent to the development and launching of a business plan designed to generate significant incremental and new revenue stream from third party medical waste services. See Disposal Facility section above for further information regarding the purchase of the Carthage, Texas facility and addition of autoclave technology.

#### Proper Disposal of Medical Sharps

The first significant regulatory development occurred in December 2004 with the improved guidance issued by the Environmental Protection Agency (“EPA”) regarding the safe disposal of medical sharps (needles, syringes and lancets). This new guidance is a result of disposal problems created by the estimated 2 billion syringes discarded annually by legal self-injectors of medicines in homes and non-healthcare commercial facilities. Until December 2004, the EPA guidance has instructed consumers to place used sharps in a household container and to place the container in the household garbage. New guidance posted on the EPA website reflects information about alternative disposal methods including mail-back programs. The improved guidance issued by the EPA is a significant step toward the removal of needles, syringes and other sharps from the solid waste stream, consistent with the current practice in healthcare facilities. The Company’s products and services, which are included in the EPA list of recommended solutions, are designed to improve safety, efficiency and patient concerns related to the proper disposal of medical sharps.

The next regulatory development was the enactment of California Senate Bill 1362, “The Safe Needle Disposal Act of 2004.” This legislation authorizes California agencies to expand the scope of their existing household hazardous waste plans to provide for the safe disposal of medical sharps including hypodermic needles and syringes. Authorized disposal programs include the mail-back programs currently marketed by the Company.

In July 2006, the State of California passed Senate Bill 1305 (“SB 1305”), an amendment to The Medical Waste Management Act. The new law requires the proper disposal of home-generated sharps waste (syringes, needles, lancets, etc.) and acknowledges mail-back programs as a convenient method for the collection and destruction of home-generated sharps. Effective January 1, 2007 (with enforcement beginning September 1, 2008), SB 1305 addresses the need to meet the changing demands of healthcare provided in alternate sites that currently allow hundreds of millions of home-generated sharps waste to be disposed in solid waste and recycling containers. The new law is designed to ensure appropriate disposal of sharps waste necessary to protect the general public and workers from potential exposure to contagious diseases and health and safety risks.

Also in July 2006, The Massachusetts Legislature enacted Senate Bill 2569 which requires the Massachusetts department of public health, in conjunction with other relevant state and local agencies and government departments, to design, establish and implement a program for the collection and disposal of non-commercially generated, spent hypodermic needles and lancets. Recommended disposal methods include mail-back products approved by the U.S. Postal Service such as the Sharps Disposal By Mail Systems®. The Massachusetts legislation addresses the need for proper disposal of used syringes, needles and lancets outside of the traditional healthcare setting.

In addition to California and Massachusetts, many other states are considering similar legislation.

In August 2007, the U.S. House of Representatives and U.S. Senate introduced bills 3251 and 1909, respectively, which would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes through a sharps-by-mail or similar program. This legislation proposes Medicare coverage for the safe needle disposal for approximately 1.3 million insulin-dependent diabetic beneficiaries and is intended to reduce the number of accidental injuries, infections and subsequent costs associated with the improper disposal of approximately 4 million needles generated daily by Medicare covered diabetics. The Company’s Sharps Disposal By Mail Systems® is an example of the cost-effective and easy-to-use solution recommended in the legislation.

#### RECENTLY ISSUED ACCOUNTING STANDARDS

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements; SFAS 157 is effective for fiscal years beginning after November 15, 2007 and for interim periods within those years. The FASB announced a one year deferral for the implementation of SFAS No. 157 for other non-financial assets and liabilities. In February, 2008, FASB issued FASB Staff Position No. FAS 157-2. This FSP defers the effective date of Statement 157 for non-financial assets and liabilities on a recurring basis (at least annually) to fiscal years beginning after November 15, 2008, and interim periods within those fiscal years for items within the scope of this FSP. The Company adopted SFAS No. 157 effective July 1, 2008, except for non financial assets and liabilities as permitted by FSP SFAS 157-2, and the adoption of such statement did not have a significant impact on our consolidated results of operations or financial position.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of FASB Statement No. 115.” This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value and establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective as of the beginning of an entity’s first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the

provisions of SFAS No. 157. The Company adopted SFAS 159 effective July 1, 2008. The Company elected to not fair value any additional financial instruments and thus the adoption of the standard did not have a material impact on its financial position and results of operations.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable

ITEM 4. CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to ensure that material information required to be disclosed in the Company's periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. The Company's disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including, its principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

As of December 31, 2008 the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the chief executive officer and the chief financial officer, of the effectiveness of the design and operation of the disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, the Company's chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures were effective, as of the end of the period covered by this report (December 31, 2008).

During the second quarter of the fiscal year 2009, there were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected or are reasonably likely to materially affect internal control over financial reporting.

The certifications required by Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits 31.1 and 31.2, respectively, to this Quarterly Report on Form 10-Q.



## PART II – OTHER INFORMATION

## ITEM 1. LEGAL PROCEEDINGS

## Ronald E. Pierce Matter

On July 15, 2008, the Company received a demand for arbitration from Ronald E. Pierce related to a June 2004 issue summarized below:

On June 14, 2004, the Company provided Mr. Ronald E. Pierce, its then current Chief Operating Officer (“Mr. Pierce”), with notice of non-renewal of his employment agreement. As such, July 14, 2004 was Mr. Pierce’s last day of employment. The Company has advised Mr. Pierce that under the terms of the employment contract no further compensation (including services) was due. The Company then received various letters from Mr. Pierce’s attorney advising that Mr. Pierce is taking the position that the non-renewal of the employment agreement was not timely and, therefore, Mr. Pierce was terminated without cause. Additionally, Mr. Pierce claims that the Company had no right to terminate him on the anniversary date of his agreement without the obligation of paying Mr. Pierce as if he were terminated without cause. The Company believes that notice of such non-renewal was timely, and that in accordance with Mr. Pierce’s employment agreement, the Company was entitled to provide notice thirty (30) days prior to the anniversary of its intent to terminate the agreement, and no severance would therefore be due to Mr. Pierce.

The claim amount under the July 15, 2008 demand for arbitration is \$300,001.

On July 18, 2008, the Company responded to the July 15, 2008 request for Arbitration from Mr. Pierce. In its response, the Company advised that the request for arbitration was filed more than four (4) years from the date upon which Pierce knew, or should have known, of any alleged breach of contract. Accordingly, the Company does not believe it has an obligation to arbitrate a time barred claim.

The Company believes it has meritorious defenses against Mr. Pierce’s claims and has not recorded a liability related to this matter.

## ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On November 21, 2008, the Company held its Annual Meeting of shareholders whereby the following items were voted upon, (i) the election of seven directors to hold office until the next annual shareholders meeting, and (ii) other matters that may be presented at the meeting for action.

The following Directors were elected at the meeting, (i) Dr. Burt Kunik, (ii) Ramsay Gillman, (iii) John R. Grow, (iv) Parris H. Holmes, Jr., (v) F. Gardner Parker, (vi) Philip C. Zerrillo, and (vii) John Dalton.

As of September 30, 2008, the record date of the Annual Meeting, 12,787,114 shares of common stock were outstanding. At the Annual Meeting, holders of 10,164,676 shares of common stock were present in person or represented by proxy. The following sets forth information regarding the results of the voting at the Annual Meeting.

	Votes in Favor	Votes Withheld
Proposal No. 1		
Dr. Burt Kunik	10,092,226	72,450
Ramsay Gillman	10,091,858	72,818
John R. Grow	10,092,226	72,450
Parris H. Holmes, Jr.	9,972,262	192,414

Edgar Filing: SHARPS COMPLIANCE CORP - Form 10-Q

F. Garder Parker	10,092,226	72,450
Philip C. Zerrillo	10,091,858	72,818
John W. Dalton	10,092,226	72,450
Proposal No. 2		
Amend 1993 Stock Plan	7,668,878	1,856,233

ITEM 6. EXHIBITS

(a)Exhibits:

- 31.1 Certification of Chief Executive Officer in Accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
- 31.2 Certification of Chief Financial Officer in Accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
- 32.1 Certification of Chief Executive Officer in Accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)
- 32.2 Certification of Chief Financial Officer in Accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

ITEMS 2, 3, AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

REGISTRANT:

SHARPS COMPLIANCE CORP.

Dated: February 13, 2009

By: /s/ Dr. Burton J. Kunik  
Chairman of the Board of Directors,  
and Chief Executive Officer

Dated: February 13, 2009

By: /s/ David P. Tusa  
Executive Vice President,  
Chief Financial Officer,  
Business Development and  
Corporate Secretary